MedTrace Logo

Evaluation of the Effect of Wet Cupping (Hijama) on Primary Fibromyalgia

NCT06320262 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2024-12-30

No results posted yet for this study

Summary

Fibromyalgia has become one of the most prevalent chronic pain conditions that impair quality of life. Wet cupping has gained increasing popularity in treating painful conditions.

This study aims to investigate the effectiveness of wet cupping therapy combined with home-based exercise compared to home-based exercise alone in improving patients diagnosed with primary fibromyalgia syndrome.

Conditions

  • Treatment

Interventions

PROCEDURE

Wet cupping therapy (WCT)

Type of cupping: Triple-stage wet cupping therapy (Hijama) will be used; sucking, scarification, sucking. Cupping points will include one cup on the posterior median line, in the depression below the processus spinosus of the 7th cervical vertebra (Alkahil area); two points in the inter-scapular region 3cm lateral to the lower border of the spinous process of the 3rd thoracic vertebra, two points at inferior angle of the scapula (3cm lateral to lower border of the spinous process of the 7th thoracic vertebra, 2 points at lumbar regions, in addition to the most painful areas. After the procedure: Areas of cupping will be covered using sterile gauze. All used tools and materials will be collected in red bags to ensure proper waste disposal. Sharp objects will be disposed of in the sharps disposal box. Telephone follow-up with all patients 48 hours after cupping will be done.

Sponsors & Collaborators

  • Rasmia Elgohary

    lead OTHER

Principal Investigators

  • Mohamed Yousef, Professor · Kasr Alainy School of Medicine, Cairo University, Egypt

  • Maha M Sabr, Professor · National Research Center (NRC)

  • Dalia B Abdelbaky, A. Prof. · National Cancer Institute (NCI)

  • Dalia M Afifi, Consultant · Agouza Rheumatology and Rehabilitation, Armed Forces, Egypt

  • Gehad G Maghraby, Lecturer · Kasr Alainy School of Medicine, Cairo University, Egypt

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-12-26
Primary Completion
2025-10-31
Completion
2025-12-31

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06320262 on ClinicalTrials.gov